BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Career Advice

  Job Ghosting, Ghost Jobs Top Job Hunt Complaints, BioSpace Finds

  A BioSpace LinkedIn poll found that job ghosting and ghost jobs are the biggest pet peeves for applicants now. Recruitment Manager Greg Clouse offers advice on dealing with them.

  February 13, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Obesity

  Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments

  Obesity drug developers Aardvark, Helicore and Metsera have all netted raises in the past two weeks.

  February 13, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Business

  Navigating Patient Journeys with Tom Whitehead

  In this episode, presented by the Genscript Biotech Global Forum 2025, BioSpace’s Head of Insights Lori Ellis and Tom Whitehead continue to discuss the patient and caregiver experience, where Tom gives his insights to the future of CGTs.

  February 13, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Career Advice

  Career Coach: How to Recover From a Bad Interview

  Plus, how to use your network effectively and create job opportunities before they exist

  February 13, 2025

   · 

  5 min read

   · 

  Carina Clingman
• 

  GLP-1

  Novo’s Semaglutide Shows Promise for Alcohol Use Disorder

  The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for addictive disorders.

  February 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  SCOPE Summit 2025 Key Takeaways: A Look Inside, Outside and Beyond the Cybersecurity Wall

  Jay Ferro, EVP, CIO, CPO & CTO at Clario discusses safety, trust and what keeps him up at night.

  February 13, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Neuropsychiatric disorders

  Newleos Raises $93.5M to Advance Neuropsychiatric Cast-Offs from Roche

  Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

  February 13, 2025

   · 

  3 min read

   · 

  Dan Samorodnitsky
• 

  Approvals

  Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas

  Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate cancer, while recent readouts also position the pharma as a strong contender in colorectal cancer and bladder cancer.

  February 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Roche’s Evrysdi Becomes First Pill Cleared for Spinal Muscular Atrophy

  Evrysdi is the first, and so far only, noninvasive disease-modifying treatment for spinal muscular atrophy.

  February 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  Sanofi Hit With $250M Impairment After Scrapping J&J-Partnered E. coli Vaccine

  Without providing specific data, Sanofi on Thursday announced that the experimental vaccine did not significantly prevent invasive E. coli disease versus placebo.

  February 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac